Latest News and Press Releases

Proposed all stock merger values VivoPower equity at US$556 million (implying a share price of US$101 per VVPR share) with FAST equity valued at US$578 million VivoPower expected to issue 5.72...

Sansure Biotech Inc (“Sansure”) is a US$1.4bn market capitalisation in vitro diagnostic solutions company listed on Shanghai Stock Exchange Mpox virus footprint has significant overlap with key...

Annual consolidated revenue of $11.8 million down 22% year-on-year (“y-o-y”) reflecting a strategic focus towards the Electric Vehicle and Sustainable Energy Solutions business units and...

Independent third-party fairness opinion was obtained and satisfactorily completed Pro forma fully diluted combined enterprise value assumes no public trust redemptions LONDON, Aug. 29, 2024 ...

Exclusivity period for Heads of Agreement extended to 31 August 2024 Extension to enable Tembo to consummate material transaction and update disclosure LONDON, July 30, 2024 (GLOBE NEWSWIRE) --...

Exclusivity period for Heads of Agreement extended to 31 August 2024 Extension to enable Tembo to consummate material transaction and update disclosure LONDON, July 29, 2024 (GLOBE NEWSWIRE) --...

Agreement consolidates major shareholder loan into single US$34m tranche Extends tenure of non-dilutive financing at VivoPower level Loan amended to be all non-current status, improving...

Exclusivity period for Heads of Agreement extended to 31 July 2024 LONDON, July 03, 2024 (GLOBE NEWSWIRE) -- the Nasdaq listed B Corp, VivoPower International PLC (Nasdaq: VVPR, “VivoPower”),...

Exclusivity period for Heads of Agreement extended to 31 July 2024 LONDON, July 02, 2024 (GLOBE NEWSWIRE) -- the Nasdaq listed B Corp, VivoPower International PLC (Nasdaq: VVPR,...

LONDON, July 02, 2024 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR, "VivoPower” or the "Company”) is pleased to announce that it has completed the sale of one of its non-core...